February 26, 2026

🚀 Cardiawave continues to push innovation while keeping clinical development efficient and impactful!
 
We are proud to be featured in Biotech Finances following a major milestone: the CE marking for our non‑invasive ultrasound-based treatment for severe aortic stenosis.
 
Our CEO, Carine Schorochoff, highlights our approach:
👉 a highly skilled and agile internal team,
👉 strategic use of external partners only where they add real value,
👉 rigorous execution with optimized resources and controlled costs.
 
🔗 Read the article (Biotech Finances subscribers only):
https://biotech-finances.com/essais-cliniques-reduire-les-couts-sans-mettre-en-peril-ses-resultats/
 
💙 Thank you to @Biotech Finances for showcasing our work.
At Cardiawave, we believe innovation thrives when agility meets expertise.
 
#MedTech #StructuralHeart #Innovation #AorticStenosis #CardiovascularInnovation #Valvosoft #medtech #focusedultrasound #innovation #NIUT #TAVI #TAVR #AorticValve #lifetimemanagementofas #valves #CEMarking
 
#FrenchCare #Health20 @france-biotech @medicen-paris-region @bpi-france @focusedultrasoundfoundation @eic-scalingclub @snitem